A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer Compared to Nab-paclitaxel+Gemcitabine Treatment

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    750
  • sponsor
    Ipsen
Updated on 1 September 2021
Investigator
Ipsen Recruitment Enquiries
Primary Contact
Messino Cancer Center (6.4 mi away) Contact
+273 other location

Summary

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

Details
Condition Metastatic Adenocarcinoma of the Pancreas
Treatment Gemcitabine, Oxaliplatin, Nab-paclitaxel, Leucovorin, 5Fluorouracil, Irinotecan Liposomal Injection
Clinical Study IdentifierNCT04083235
SponsorIpsen
Last Modified on1 September 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note